Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,029 MXN
Change Today -53.27 / -4.92%
Volume 230.0
As of 4:09 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by BAXTER INTERNATIONAL INC (BAX*) in the last 6 months

Announced 05/12/15
900.00M for Sigma-Tau Pharma Limited UK
Merger/Acquisition

Baxter International Inc. (NYSE:BAX) entered into an agreement to acquire Sigma Tau Pharma Ltd. from Sigma Tau Finanziaria S.p.A. for $900 million on May 12, 2015. The purchase price of $900 million is before working capital and other transaction adjustments. Baxter International expects to finance the transaction through a combination of foreign cash and debt. The transaction is expected to close in the third quarter of 2015. The Oncaspar portfolio records annual sales ...
Read More


BAX*'s price was unchanged after the transaction was announced on 05/12/15.
Investor / Buyer
Baxter International Inc.
Creditor / Lender
Sigma Tau Finanziaria S.p.A.
 
Announced 03/3/15
200.00M for SuppreMol GmbH
Merger/Acquisition

Baxter International Inc. (NYSE:BAX) acquired SuppreMol GmbH from group of investors for €200 million on March 3, 2015. As a part of the purchase consideration, Baxter International will pay €65 million to MIG Verwaltungs AG for 32.45% stake in SuppreMol GmbH, of which €9.5 million will be held initially in custody in an escrow account to protect the guarantee claims of Baxter International for 18 months and the concerned MIG funds will only receive this after the expiration ...
Read More


BAX*'s price was unchanged after the transaction was announced on 03/3/15.
Investor / Buyer
Baxter International Inc.
Creditor / Lender
Bayern Kapital GmbH
BioMedInvest AG I
BioMedPartners AG
FCP Biotech Holding GmbH
FCPB SUP GmbH
HMW Emissionshaus AG
KfW Mittelstandsbank, Investment Arm
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Endowment Arm
MIG Fund 11
MIG Fund 12
MIG Fund 13
MIG Fund 2
MIG Fund 4
MIG Fund 5
MIG Fund 8
MIG Verwaltungs AG
Santo Holding (Deutschland) GmbH
Z-cube S.r.l.
 
Announced 12/15/14
Baxter International Inc., Vero Cell Platform and Related Assets
Merger/Acquisition

Nanotherapeutics, Inc. entered into a definitive agreement to acquire Vero cell platform and related assets from Baxter International Inc. (NYSE:BAX) on December 15, 2014.


BAX*'s price was unchanged after the transaction was announced on 12/15/14.
Investor / Buyer
Nanotherapeutics, Inc.
Creditor / Lender
Baxter International Inc.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $1,028.70 MXN -53.27

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,828 JPY +12.00
Kimberly-Clark Corp $110.33 USD +0.42
Mylan NV $72.04 USD +1.49
Stryker Corp $96.59 USD +1.06
Takeda Pharmaceutical Co Ltd ¥6,039 JPY +86.00
View Industry Companies
 

Industry Analysis

BAX*

Industry Average

Valuation BAX* Industry Range
Price/Earnings 19.8x
Price/Sales 2.2x
Price/Book 5.0x
Price/Cash Flow 15.4x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.